Clear cell renal cell carcinoma is the most common subtype among renal cell carcinoma.2, 39 In the past few decades, great progress has been made from a non‐specific immune approach to targeted therapy (against VEGF, PDGF) and now to novel immunotherapy with immune‐checkpoint inhibitors.31 At present, indolent and aggressive tumours cannot be distinguished depending on TNM staging system, which mainly relies on anatomical information without biological characteristics. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.